Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps
Respiratory Research, Volume 12, Article 38, Year 2011
Notification
URL copied to clipboard!
Description
Background: Adjusting medication for uncontrolled asthma involves selecting one of several options from the same or a higher treatment step outlined in asthma guidelines. We examined the relative benefit of introducing budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (Symbicort SMART® Turbuhaler®) in patients previously prescribed treatments from Global Initiative for Asthma (GINA) Steps 2, 3 or 4.Methods: This is a post hoc analysis of the results of five large clinical trials (>12000 patients) comparing BUD/FORM maintenance and reliever therapy with other treatments categorised by treatment step at study entry. Both current clinical asthma control during the last week of treatment and exacerbations during the study were examined.Results: At each GINA treatment step, the proportion of patients achieving target levels of current clinical control were similar or higher with BUD/FORM maintenance and reliever therapy compared with the same or a higher fixed maintenance dose of inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) (plus short-acting β2-agonist [SABA] as reliever), and rates of exacerbations were lower at all treatment steps in BUD/FORM maintenance and reliever therapy versus same maintenance dose ICS/LABA (P < 0.01) and at treatment Step 4 versus higher maintenance dose ICS/LABA (P < 0.001). BUD/FORM maintenance and reliever therapy also achieved significantly higher rates of current clinical control and significantly lower exacerbation rates at most treatment steps compared with a higher maintenance dose ICS + SABA (Steps 2-4 for control and Steps 3 and 4 for exacerbations). With all treatments, the proportion of patients achieving current clinical control was lower with increasing treatment steps.Conclusions: BUD/FORM maintenance and reliever therapy may be a preferable option for patients on Steps 2 to 4 of asthma guidelines requiring a more effective treatment and, compared with other fixed dose alternatives, is most effective in the higher treatment steps. © 2011 Bateman et al; licensee BioMed Central Ltd.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC3082240/bin/1465-9921-12-38-S1.DOC
Authors & Co-Authors
Bateman, E. D.
South Africa, Cape Town
University of Cape Town
Harrison, Tim W.
United Kingdom, Nottingham
University of Nottingham
Quirce, Santiago
Spain, Madrid
Universidad Autónoma de Madrid
Reddel, Helen K.
Australia, Sydney
Woolcock Institute of Medical Research
Buhl, Roland Otto
Germany, Mainz
Universitätsmedizin Mainz
Humbert, Marc
France, Gif-sur-yvette
Université Paris-saclay
Jenkins, Christine R.
Australia, Sydney
Woolcock Institute of Medical Research
Peterson, Stefan
Sweden, Sodertalje
Astrazeneca Sweden
Östlund, Ollie
Sweden, Sodertalje
Astrazeneca Sweden
O'Byrne, Paul M.
Canada, Hamilton
Michael G. Degroote School of Medicine
Sears, Malcolm R.
Canada, Hamilton
Michael G. Degroote School of Medicine
Eriksson, Göran
Sweden, Sodertalje
Astrazeneca Sweden
Sweden, Lund
Skånes Universitetssjukhus
Statistics
Citations: 60
Authors: 12
Affiliations: 9
Identifiers
Doi:
10.1186/1465-9921-12-38
ISSN:
14659921
e-ISSN:
1465993X
Research Areas
Genetics And Genomics